1[1]Sawyers C L.Chronic myeloid leukemia.N Engl J Med,1999,340:1330-1440.
2[2]Druker B J,Talpaz M,Resta D J,et al.Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine in chronic myeloid leukemia.N Eng J Med,2001,344:1038-1042.
3[3]Druker B J,Sawyers C L,Kantarjian H,et al.Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.N Eng J Med,2001,344:1038-1042.
4[4]Mauro M J,Druker B J.STI571:Targeting BCR-ABL as therapy for CML.Oncology,2001,6:233-238.
5[5]Hochhaus A,Reiter A,Saussele S,et al.Molecular heterogeneity in complete cytogenetic responders after interferon-α therapy for chronic myelogeneous leukemia:Low levels of minimal residual disease are associated with continuing remission .Blood,2000,95:62-66.
6[6]Hehlmann R,Hochhaus A S,Kolb H J,et al.Interferon-α before allogeneic bone marrow transplantation in chronic myelogenous leukemia does not affect outcome adversely provided it is discontinued at least 90 days before the procedure .Blood,1999,94:3668-3677.
7[7]Elmaagacli A H,Beelen D W,Opalka B,et al.The risk of residual molecular and cytogenetic disease in patients with Philadelphia chromosome positive chronic phase myelogenous leukemia is reduced after transplantation of allogeneic peripheral blood stem cells.Blood,1999,94:384-389.
8[8]Drobyski W R,Hessner M J,Klein J P,et al .T-cell depletion plus salvage immunotheray with donor leukcyte infusions as a strategy to treat chronic phase chronic myelogenous leukemia patient undergoing HLA-identical sibling marrow transplantation.Blood,1999,94:434-441.
9[9]Dazzi F,Szydlo R M,Craddock C,et al.Comparison of single dose and escalating dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia .Blood,2000,95:67-71.
10[10]Carella A M,Lerma E,Corsetti M T,et al.Autografting with Ph-chromosome negative mobilized hematopoietic stem cell in chronic myelogenous leukemia.Blood,1999,83:1534-1539.
